PARP Inhibitors in Ovarian and Other Cancers

Clinical Advances in Hematology & Oncology May 2015, Volume 13, Issue 5 Ruth Plummer, MA, BMBCh, DPhil, MD, FRCP Professor of Experimental Cancer Medicine, Newcastle University, Newcastle […]

The National Cancer Institute’s Experimental Therapeutics Clinical Trials Network

Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3 S. Percy Ivy, MD, Associate Chief, Cancer Therapy Evaluation Program, Investigational Drug Branch, Division of Cancer Treatment […]

Redefining Dose-Limiting Toxicity

Clinical Advances in Hematology & Oncology February 2015, Volume 13, Issue 2 Sophie Postel-Vinay, MD, PhD, Drug Development Department, Institut Gustave Roussy, Villejuif, France H&O How are […]

Use of Predictive Biomarkers in Phase 2 Trials

Clinical Advances in Hematology & Oncology January 2015, Volume 13, Issue 1 Janet E. Dancey, MD, Professor, Department of Oncology, Director, NCIC Clinical Trials Group, Queen’s University School […]

What Is the Role of Journalists in Distinguishing Hype From Reality?

Clinical Advances in Hematology & Oncology December 2014, Volume 12, Issue 12 Paul Goldberg, Editor and Publisher, The Cancer Letter, Washington, DC H&O What are the most important traits […]

Translational Research in the National Cancer Institute’s Cooperative Groups

Clinical Advances in Hematology & Oncology November 2014, Volume 12, issue 11 W. Fraser Symmans, MD, Professor and Director of Research Operations, Department of Pathology, University of Texas […]

Unleashing the Power of Preemptive Pharmacogenomics

Clinical Advances in Hematology & Oncology October 2014, Volume 12, Issue 10 Peter H. O’Donnell, MD Assistant Professor of Medicine, University of Chicago, Chicago, Illinois H&O What […]

The Promise of Genomics-Based Drug Repurposing

Clinical Advances in Hematology & Oncology September 2014, Volume 12, Issue 9 Joel Dudley, PhD, Assistant Professor of Genetics and Genomics Sciences, Director of Biomedical Informatics, Icahn […]

Incorporating Biomarkers Into Drug Labeling

Clinical Advances in Hematology & Oncology August 2014, Volume 12, Issue 8 Mark J. Ratain, MD Leon O. Jacobson Professor of Medicine, Director, Center for Personalized Therapeutics, Associate Director […]

Heritable Resistance to Tyrosine Kinase Inhibitors

July 2014, Volume 12, Issue 7 S. Tiong Ong, MA, MRCP Associate Professor, Cancer and Stem Cell Biology Program, Duke-National University of Singapore Graduate Medical School Singapore and Department of Medicine, Duke […]

Mining the Internet for Drug Information

Clinical Advances in Hematology & Oncology June 2014, Volume 12, Issue 6 Nigam Shah, MBBS, PhD, Assistant Professor of Medicine, Stanford University School of Medicine, Stanford, California H&O How did […]

Clinical Trial Design for Phase 1 Studies of Drug Combinations

Clinical Advances in Hematology & Oncology May 2014, Volume 12, Issue 5 Channing Paller, MD Assistant Professor of Oncology Johns Hopkins University Baltimore, Maryland Member, Clinical […]

Clinical Implementation of Next-Generation Sequencing

Clinical Advances in Hematology & Oncology April 2014, Volume 12, Issue 4 Richard D. Press, MD, PhD Director of Molecular Pathology, Department of Pathology & Knight Cancer Institute, Oregon […]

Genetic Engineering of T Cells in Leukemia and Lymphoma

Clinical Advances in Hematology & Oncology March 2014, Volume 12, Issue 3 James N. Kochenderfer, MD Investigator, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland H&O How does chimeric […]

Biomarkers in Castration-Resistant Prostate Cancer

Clinical Advances in Hematology & Oncology February 2014, Volume 12, Issue 2 Biomarkers in Castration-Resistant Prostate Cancer Andrew J. Armstrong, MD, Associate Professor of Medicine and Surgery, Duke […]

New Drugs and Treatment Strategies in Prostate Cancer

Clinical Advances in Hematology & Oncology January 2014, Volume 12, Issue 1 Matthew D. Galsky, MD Associate Professor of Medicine, Hematology, and Medical Oncology Icahn School of […]

Neoadjuvant Pertuzumab in Early HER2-Positive Breast Cancer

Clinical Advances in Hematology & Oncology December 2013, Volume 11, Issue 12 Neoadjuvant Pertuzumab in Early HER2-Positive Breast Cancer Mikkael A. Sekeres, MD, MS , Director, Leukemia Program, Professor […]

Update on Ibrutinib

Clinical Advances in Hematology & Oncology November 2013, Volume 11, Issue 11 Update on Ibrutinib Susan M. O’Brien, MD, Ashbel Smith Professor, Department of Leukemia, Division of Cancer Medicine, UT MD […]

New Drugs for Gastrointestinal Stromal Tumors

Clinical Advances in Hematology & Oncology October 2013, Volume 11, Issue 10 Christopher Garrett, MD Associate Professor Department of Gastrointestinal Medical Oncology Division of Cancer Medicine The […]

Metformin’s Potential in Oncology

Clinical Advances in Hematology & Oncology September 2013, Volume 11, Issue 9 Michael Pollak, MD Alexander Goldfarb Research Chair and Professor, Department of Oncology, Department of Medicine, McGill […]